CAS No. :	610798-31-7
Formula :	C₂₂H₂₁N₃O₄
M.W :	391.42
SMILES Code :	C#CC1=CC(NC2=C3C=C(OCCOCCOCCO4)C4=CC3=NC=N2)=CC=C1
Synonyms :	BPI-2009; BPI 2009H; Conmana
MDL No. :	MFCD22124501
InChI Key :	QQLKULDARVNMAL-UHFFFAOYSA-N
Pubchem ID :	22024915

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

PC9 and HCC827 cells	10 µM	24, 48, 72 and 96 hours	Detected cell viability by MTT assay	Biomark Res. 2023 May 12;11(1):51.
H1975	2 µM	4 weeks	Assess cell viability and clonogenic capacity, H1975 was resistant to icotinib	J Exp Clin Cancer Res. 2022 Jun 11;41(1):200.
PC-9/GR	2 µM	4 weeks	Assess cell viability and clonogenic capacity, PC-9/GR was resistant to icotinib	J Exp Clin Cancer Res. 2022 Jun 11;41(1):200.
Human liver microsomes (HLMs)	0.2–60 µM	40 minutes	Evaluate the inhibitory effect of Icotinib on UGT1A1-mediated NCHN-O-glucuronidation, showing an IC50 value of 5.15 μmol/L as a noncompetitive inhibitor	Acta Pharm Sin B. 2017 Nov;7(6):657-664.
HCC4006	5 µM	48 hours	Evaluate the growth inhibitory effect of BDMC and icotinib combination on EGFR-TKI-sensitive NSCLC cells, results showed that the combination treatment had a minor effect on cell viability.	Int J Biol Sci. 2020 Mar 5;16(9):1536-1550.
A549	5 µM	48 hours	Evaluate the growth inhibitory effect of BDMC and icotinib combination on EGFR-TKI-resistant NSCLC cells, results showed that the combination treatment significantly reduced cell viability.	Int J Biol Sci. 2020 Mar 5;16(9):1536-1550.
H1781	5 µM	48 hours	Evaluate the growth inhibitory effect of BDMC and icotinib combination on EGFR-TKI-resistant NSCLC cells, results showed that the combination treatment significantly reduced cell viability.	Int J Biol Sci. 2020 Mar 5;16(9):1536-1550.
H460	5 µM	48 hours	Evaluate the growth inhibitory effect of BDMC and icotinib combination on EGFR-TKI-resistant NSCLC cells, results showed that the combination treatment significantly reduced cell viability.	Int J Biol Sci. 2020 Mar 5;16(9):1536-1550.
H1975	6.25, 12.5, 25, 50, 100 µM	48 hours	Evaluate the sensitivity of H1975 cells to Icotinib, results showed H1975 cells were resistant to Icotinib.	Int J Mol Med. 2019 Aug;44(2):437-446.
H1650	6.25, 12.5, 25, 50, 100 µM	48 hours	Evaluate the sensitivity of H1650 cells to Icotinib, results showed H1650 cells were resistant to Icotinib.	Int J Mol Med. 2019 Aug;44(2):437-446.
A549	6.25, 12.5, 25, 50, 100 µM	48 hours	Evaluate the sensitivity of A549 cells to Icotinib, results showed A549 cells were resistant to Icotinib.	Int J Mol Med. 2019 Aug;44(2):437-446.
HCC827	6.25, 12.5, 25, 50, 100 µM	48 hours	Evaluate the sensitivity of HCC827 cells to Icotinib, results showed HCC827 cells were sensitive to Icotinib.	Int J Mol Med. 2019 Aug;44(2):437-446.
HCC827	0, 2, 4, 8, 16, 32 µM	48 hours	To measure the sensitivity of HCC827 cells to Icotinib, results showed HCC827 cells were sensitive to Icotinib with IC50 of 8.1 μM.	Respir Res. 2019 Oct 12;20(1):217.
Recombinant human UGT1A1	0.2–60 µM	50 minutes	Evaluate the inhibitory effect of Icotinib on UGT1A1-mediated NCHN-O-glucuronidation, showing an IC50 value of 8.76 μmol/L as a noncompetitive inhibitor	Acta Pharm Sin B. 2017 Nov;7(6):657-664.
H460	23.60 ± 0.30 µM (IC50)	72 hours	Evaluate the growth inhibitory effect of Icotinib on H460 cells, results showed H460 cells were less sensitive to Icotinib.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.
H1299	19.50 ± 2.86 µM (IC50)	72 hours	Evaluate the growth inhibitory effect of Icotinib on H1299 cells, results showed H1299 cells were less sensitive to Icotinib.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.
HCC827	24.40 ± 2.88 nM (IC50)	72 hours	Evaluate the growth inhibitory effect of Icotinib on HCC827 cells, results showed HCC827 cells were sensitive to Icotinib.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.
H1975	18.80 ± 0.40 µM (IC50)	72 hours	Evaluate the growth inhibitory effect of Icotinib on H1975 cells, results showed H1975 cells were less sensitive to Icotinib.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.
A549	21.8 ± 0.60 µM (IC50)	72 hours	Evaluate the growth inhibitory effect of Icotinib on A549 cells, results showed A549 cells were less sensitive to Icotinib.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.
PC-9	26.80 ± 3.62 nM (IC50)	72 hours	Evaluate the growth inhibitory effect of Icotinib on PC-9 cells, results showed PC-9 cells were sensitive to Icotinib.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.
H1975	52.427±2.059 µM (IC50)	72 hours	Evaluate the anti-proliferative effect of Icotinib on H1975 cells, results showed H1975 cells were non-sensitive to Icotinib.	J Cancer. 2019 Jan 29;10(5):1275-1287.
HCC827IR	25.115±2.240 µM (IC50)	72 hours	Evaluate the anti-proliferative effect of Icotinib on HCC827IR cells, results showed HCC827IR cells were non-sensitive to Icotinib.	J Cancer. 2019 Jan 29;10(5):1275-1287.
HCC827	0.0126±0.0001 µM (IC50)	72 hours	Evaluate the anti-proliferative effect of Icotinib on HCC827 cells, results showed HCC827 cells were sensitive to Icotinib.	J Cancer. 2019 Jan 29;10(5):1275-1287.
HCC827/IcoRH	0.01–20 µM	96 hours	Evaluate icotinib sensitivity, results showed significantly lower sensitivity in resistant cells compared to parental cells	Biomark Res. 2021 Jan 30;9(1):9.
HCC827/IcoRL	0.01–20 µM	96 hours	Evaluate icotinib sensitivity, results showed significantly lower sensitivity in resistant cells compared to parental cells	Biomark Res. 2021 Jan 30;9(1):9.
PC9/IcoRH	0.01–20 µM	96 hours	Evaluate icotinib sensitivity, results showed significantly lower sensitivity in resistant cells compared to parental cells	Biomark Res. 2021 Jan 30;9(1):9.
PC9/IcoRL	0.01–20 µM	96 hours	Evaluate icotinib sensitivity, results showed significantly lower sensitivity in resistant cells compared to parental cells	Biomark Res. 2021 Jan 30;9(1):9.
HCC827IR	50 µM	Over 6 monthourss	To establish an Icotinib-resistant cell model, HCC827IR cells showed IC50>80 μM, indicating resistance to Icotinib.	Respir Res. 2019 Oct 12;20(1):217.

BALBL/c nude mice	H460 cell xenograft model	Oral gavage	125 mg/kg icotinib and 100 mg/kg BDMC	Once daily for 21 days	Evaluate the anti-tumor effect of BDMC and icotinib combination on H460 cell xenograft model, results showed that the combination treatment significantly inhibited tumor growth.	Int J Biol Sci. 2020 Mar 5;16(9):1536-1550.
Nude mice	Subcutaneous xenograft model	Oral	50 mg/kg	21 days	Evaluate the anti-tumor effect of Icotinib in vivo, found that STAT3/FOXM1 signaling blockade reversed resistance	J Exp Clin Cancer Res. 2022 Jun 11;41(1):200.
Nude mice	Subcutaneous xenograft model	Oral	50 mg/kg	Every three days for three weeks	Evaluate the antitumor effect of icotinib in vivo, results showed lower sensitivity to icotinib in tumors formed by resistant cells	Biomark Res. 2021 Jan 30;9(1):9.
BALB/c nude mice	HCC827IR and H1975 xenograft models	Oral	50 mg/kg	Thrice weekly for 5 weeks	Evaluate the anti-tumor effect of Icotinib on HCC827IR and H1975 xenograft models, results showed Icotinib alone had limited effect on HCC827IR model and no significant effect on H1975 model.	J Cancer. 2019 Jan 29;10(5):1275-1287.
BALB/c nude mice	PC-9 xenograft model	Intratumoral injection	60 mg/kg	17 days	Evaluate the antitumor effect of Icotinib on PC-9 xenograft model in vivo, results showed Icotinib significantly inhibited tumor growth.	J Exp Clin Cancer Res. 2019 Apr 5;38(1):148.

NCT02820116	Non-small Cell Lung Cancer(NSC... More >>LC) Less <<	PHASE2	UNKNOWN	2025-04-23	Beijing Haidian Hospital, Beij... More >>ing, Beijing, 100080, China Less <<
NCT01720901	Non-small Cell Lung Cancer	PHASE4	SUSPENDED	2025-12-16	Xiangya Hospital, Central-Sout... More >>h Univercity, Changsha, Hunan, 410008, China Less <<
NCT02264210	Lung Neoplasms\|Squamous Cell L... More >>ung Cancer\|Adenocarcinoma of the Lung\|Adenosquamous Cell Lung Cancer\|Large Cell Lung Cancer\|Bronchial Neoplasms\|Stage IB Non-small Cell Lung Cancer Less <<	PHASE2	COMPLETED	2025-07-22	Sun Yat-sen University Cancer ... More >>Center, Guangzhou, Guangdong, 510060, China Less <<
NCT03346811	Plasma EGFR Mutation-positive ... More >>Lung Cancer Less <<	PHASE2	UNKNOWN	2020-03-10	National Cancer Center/Cancer ... More >>Hospital, Beijing, Beijing, 100021, China Less <<
NCT02960607	Carcinoma, Non-Small-Cell Lung	PHASE2	UNKNOWN	-	Chinese Academy of Medical Sci... More >>ences, Beijing, China Less <<
NCT02044328	Non-small Cell Lung Cancer	PHASE2	COMPLETED	2025-10-21	Xuanwu Hospital, Capital Medic... More >>al University, Beijing, Beijing, 100053, China Less <<
NCT01514877	Lung Cancer\|Metastatic Cancer	PHASE2	COMPLETED	2025-07-14	Zhejiang Cancer Hospital, Hang... More >>zhou, Zhejiang, 310022, China Less <<
NCT01688713	Brain Metastases\|Non-small Cel... More >>l Lung Cancer Less <<	PHASE2	UNKNOWN	2025-09-15	Zhejiang Cancer Hospital, Hang... More >>zhou, Zhejiang, 310022, China Less <<
NCT02009605	Squamous Cell Carcinoma of Lun... More >>g Less <<	PHASE2	UNKNOWN	2025-03-16	79 Qingchun Road, Hangzhou, Zh... More >>ejiang, 310003, China Less <<
NCT02934256	Vestibular Schwannoma\|Neurofib... More >>romatosis Type 2 Less <<	PHASE2	COMPLETED	2025-07-18	Beijing Tiantan Hospital Affil... More >>iated to Capital Medical University, Beijing, Beijing, 100050, China\|Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, 100050, China Less <<
NCT01963195	NSCLC	PHASE2	UNKNOWN	2025-12-19	Dept. of Oncology,The First Af... More >>filiated Hospital of Anhui Medical Univesrsity, Hefei, Anhui, 230032, China Less <<
NCT05514314	Non-Small Cell Lung Cancer	PHASE2	NOT_YET_RECRUITING	2025-06-30	-
NCT03349203	EGF-R Positive Non-Small Cell ... More >>Lung Cancer Less <<	PHASE2	UNKNOWN	2023-12-30	Cancer Hospital, Chinese Acade... More >>my of Medical Science, Beijing, China Less <<
NCT02961270	Non-small Cell Lung Cancer	PHASE2	UNKNOWN	2025-08-18	Department of Medical Oncology... More >>, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, 100021, China Less <<
NCT01855854	Adenocarcinoma of the Gastroes... More >>ophageal Junction\|Esophageal Carcinoma Less <<	PHASE2	COMPLETED	2016-01-07	Cancer Hospital, Chinese Acade... More >>my of Medical Sciences, Beijing, Beijing, 100021, China Less <<
NCT02328261	Nasopharyngeal Carcinoma	PHASE2	UNKNOWN	2025-04-17	-
NCT03396185	EGFR Gene Mutation\|Non Small C... More >>ell Lung Cancer Stage IIIA\|Non Small Cell Lung Cancer Stage IIIB Less <<	PHASE2	UNKNOWN	2023-02-01	Cancer Hospital, Chinese Acade... More >>my of Medical Science, Beijing, China Less <<
NCT02430974	Carcinoma, Non-Small-Cell Lung	PHASE2	UNKNOWN	2025-01-18	-
NCT01646450	Non-Small Cell Lung Cancer	PHASE4	UNKNOWN	2025-04-16	Shanghai Chest Hospital Afflia... More >>ted to Shanghai Jiaotong Univercity, Shanghai, Shanghai, 200030, China Less <<
NCT03749213	EGF-R Positive Non-Small Cell ... More >>Lung Cancer Less <<	PHASE2	UNKNOWN	2024-12-30	Cancer Hospital, Chinese Acade... More >>my of Medical Science, Beijing, China Less <<
NCT02362230	Metastatic Breast Cancer	PHASE2	TERMINATED	2020-12-15	Sun Yat-sen University, Cancer... More >> Center, Guangzhou, Guangdong, 510060, China Less <<
NCT01465243	Non-small Cell Lung Cancer	PHASE4	COMPLETED	2025-02-14	307 Hospital of People's Liber... More >>ation Army（PLA）, Beijing, Beijing, 100071, China Less <<
NCT03992885	Non-squamous Non-small Cell Lu... More >>ng Cancer Less <<	PHASE3	RECRUITING	2025-08-01	Department of Pulmonary Medica... More >>l Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, 300060, China Less <<

{[proInfo.proName]}

CAS No.: 610798-31-7

{[proInfo.proName]}

CAS No.: 610798-31-7

Alternative Products

Product Details of Icotinib

Safety of Icotinib

Related Pathways of Icotinib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.55mL 0.51mL 0.26mL	12.77mL 2.55mL 1.28mL	25.55mL 5.11mL 2.55mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed